SEOUL, April 16 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. said Thursday its breast cancer biosimilar Ontruzant is now available in the United States. Global health care company MSD has begun distributing the biosimilar that references Switzerland-based Roche Holding’s Herceptin, also known as Trastuzumab, in the world’s largest pharmaceutical market, Samsung Bioepis [...]
SEOUL, Nov. 16 (Korea Bizwire) – Technology Licensing Offices at hospitals, universities and research labs had successfully inked 405 technology transfer deals with businesses as of October, the Ministry of Health and Welfare revealed on November 15. Technology Licensing Offices, commonly referred to as TLOs, are organizations set up as intermediaries that serve as the [...]
SEOUL, Aug. 8 (Korea Bizwire) – Samsung BioLogics Co., a biosimilar firm affiliated with Samsung Group, will apply for preliminary approval this week for its initial public offering (IPO), estimated at around 3 trillion won (US$2.68 billion), South Korea’s bourse said Monday. The firm, one of the world’s largest manufacturers of biosimilar medicine, plans to [...]
SEOUL, June 9 (Korea Bizwire) – Samsung Bioepis announced the results of clinical studies on its three biosimilars on June 8, 2016, at the Annual European Congress of Rheumatology (EULAR 2016 London) which is being held in London until June 11. The three biosimilars that are currently sold in Korea and Europe include BRENZYS (Benepali in [...]
SEOUL, May 24 (Korea Bizwire) – Recent anticipation predicts that Korea’s biosimilar market will grow to a 150-billion-won industry by 2019. According to the Korea Pharmaceutical Manufacturers Association (KPMA), the industry, which was valued at 80 billion won in 2013, will grow to a 150 billion won market by 2019. The government’s active policy towards biosimilars, [...]
SEOUL, Mar. 11 (Korea Bizwire) — Samsung Group’s pharmaceutical subsidiary Samsung Bioepis will be the third Korean company to manufacture and distribute biosimilar products. The company confirmed that its ‘SB4′ Enbrel biosimilar drug has advanced into regulatory review for manufacturing and marketing by the Ministry of Food and Drug Safety (MFDS), according to an announcement on March [...]
REDWOOD CITY, Calif., Dec. 4 (Korea Bizwire) — Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call for Monday, December 15, 2014, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter 2014 financial results and [...]